{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:08Z","timestamp":1791515828602,"version":"4.3.4"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.20165","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T11:32:29Z","timestamp":1626953549000},"page":"e2120165","source":"Crossref","is-referenced-by-count":44,"title":["Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia"],"prefix":"10.1001","volume":"4","author":[{"given":"Zhe","family":"Wang","sequence":"first","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyi","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Jia","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangliu","family":"Xia","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Occupational and Environmental Health, Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"zoi210596r1","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update.","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"zoi210596r2","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"19","key":"zoi210596r3","doi-asserted-by":"publisher","first-page":"17031","DOI":"10.18632\/oncotarget.v6i19","article-title":"A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.","volume":"6","author":"Weng","year":"2015","journal-title":"Oncotarget"},{"issue":"9976","key":"zoi210596r4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia.","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"zoi210596r5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/(ISSN)1096-8652","article-title":"Imatinib mesylate as a cause of acute liver failure.","volume":"81","author":"Cross","year":"2006","journal-title":"Am J Hematol"},{"issue":"4","key":"zoi210596r6","article-title":"Novel score-based decision approach in chronic myeloid leukemia patients after acute toxic imatinib-induced liver injury.","volume":"11","author":"Lopina","year":"2019","journal-title":"Cureus"},{"issue":"19","key":"zoi210596r7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi210596r8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12809\/hkmj187420","article-title":"Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.","volume":"25","author":"Boo","year":"2019","journal-title":"Hong Kong Med J"},{"issue":"4","key":"zoi210596r9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/leu.2013.320","article-title":"Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.","volume":"28","author":"Mayer","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"zoi210596r10","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000003","article-title":"A case of severe, nilotinib-induced liver injury.","volume":"6","author":"Belopolsky","year":"2019","journal-title":"ACG Case Rep J"},{"issue":"8","key":"zoi210596r11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428190802136384","article-title":"Dasatinib-induced acute hepatitis.","volume":"49","author":"Bonvin","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"zoi210596r12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis.","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi210596r13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.2012.063172","article-title":"Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? systematic review and meta-analysis.","volume":"98","author":"Gurion","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"zoi210596r14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis.","volume":"2","author":"Mealing","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"zoi210596r15","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials.","volume":"16","author":"Yun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"zoi210596r16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2018.08.016","article-title":"Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: a systematic review and network meta-analysis.","volume":"104","author":"Fachi","year":"2018","journal-title":"Eur J Cancer"},{"key":"zoi210596r17","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2147\/CMAR","article-title":"First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis.","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"1","key":"zoi210596r18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.","volume":"16","author":"Haguet","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"zoi210596r19","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"zoi210596r20","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"zoi210596r22","first-page":"1","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996"},{"issue":"10","key":"zoi210596r23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.v89.10","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"zoi210596r24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial.","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210596r25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ejh.2015.94.issue-3","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"24","key":"zoi210596r26","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi210596r27","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"5","key":"zoi210596r28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.","volume":"124","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"24","key":"zoi210596r29","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi210596r30","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"5","key":"zoi210596r31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi210596r32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"zoi210596r33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"zoi210596r34","doi-asserted-by":"publisher","first-page":"9480","DOI":"10.18632\/oncotarget.v9i10","article-title":"Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.","volume":"9","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"zoi210596r35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bcp.2014.77.issue-6","article-title":"Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.","volume":"77","author":"Iacovelli","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"zoi210596r36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.critrevonc.2014.11.006","article-title":"Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of randomized clinical trials.","volume":"93","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"zoi210596r37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"zoi210596r38","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/tx900256y","article-title":"Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.","volume":"22","author":"Li","year":"2009","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"zoi210596r39","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1124\/dmd.109.030361","article-title":"Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"zoi210596r40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/dmd.111.040949","article-title":"Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.","volume":"40","author":"Castellino","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"zoi210596r41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1021\/acs.chemrestox.9b00205","article-title":"Involvement of pazopanib and sunitinib aldehyde reactive metabolites in toxicity and drug-drug interactions in vitro and in patient samples.","volume":"33","author":"Paludetto","year":"2020","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"zoi210596r42","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib.","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem Res Toxicol"},{"issue":"17","key":"zoi210596r43","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1200\/JCO.2009.26.5496","article-title":"Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.","volume":"28","author":"Takeda","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi210596r44","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1200\/JCO.2010.34.3368","article-title":"Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.","volume":"29","author":"Kijima","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210596r45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.taap.2012.04.010","article-title":"Oxidative stress is involved in dasatinib-induced apoptosis in rat primary hepatocytes.","volume":"261","author":"Xue","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"zoi210596r46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","article-title":"Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.","volume":"395","author":"Paech","year":"2018","journal-title":"Toxicology"},{"issue":"11","key":"zoi210596r47","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"zoi210596r48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"zoi210596r49","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3109\/00498254.2013.840750","article-title":"Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases.","volume":"44","author":"Ai","year":"2014","journal-title":"Xenobiotica"},{"issue":"1","key":"zoi210596r50","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.005","article-title":"Treatment recommendations for chronic myeloid leukemia.","volume":"6","author":"Baccarani","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"zoi210596r21","unstructured":"National Institute for Health Research. PROSPERO: international prospective register of systematic reviews. Accessed January 8, 2021. https:\/\/www.crd.york.ac.uk\/PROSPERO\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2782167\/wang_2021_oi_210596_1626282127.41987.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T11:32:39Z","timestamp":1626953559000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2782167"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20165","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}